Cancer Drug Resistance (CDR) is an international peer-reviewed, open access, online journal.

Aims and Scope

Cancer Drug Resistance is an international, peer-reviewed journal dedicated to advancing the understanding of cancer drug resistance and to improving its prediction, prevention, monitoring, and therapeutic management. The journal publishes original research, reviews, commentaries, and letters addressing the biological, molecular, cellular, pharmacological, translational, and clinical aspects of resistance to anticancer therapies.

The journal welcomes studies investigating intrinsic, acquired, and adaptive resistance, including the biological and pharmacological factors that influence tumour sensitivity, treatment response, and treatment failure. Areas of interest include, but are not limited to, drug design and delivery; drug distribution and cellular pharmacology; drug influx and efflux transporters, including ATP-binding cassette (ABC) transporters; drug targets and target modification; receptor–ligand interactions; cellular signalling pathways; drug activation, metabolism, and degradation, including Phase I and Phase II metabolism; drug sequestration; DNA damage and repair; tumour heterogeneity and evolution; epigenetic and transcriptional regulation; phenotypic plasticity; and interactions between tumour cells and the tumour microenvironment.

CDR also welcomes research on biomarkers associated with or predictive of resistance to specific anticancer treatments; approaches for detecting and monitoring resistance; clinical patterns and determinants of treatment resistance; and therapeutic strategies designed to prevent, delay, or overcome resistance, including rational combination regimens. Research may address chemotherapy, endocrine therapy, molecularly targeted agents, immunotherapy, anti-angiogenic therapy, antibody–drug conjugates (ADCs), radioligand therapies, and other anticancer treatment modalities. Both experimental and clinical studies are within scope, including research that advances resistance-related knowledge through mechanistic investigation, translational evaluation, biomarker assessment, or clinical analysis.

The central consideration for scope is the substantive relevance of the research to cancer drug resistance. Studies should address a meaningful question concerning the understanding, prediction, monitoring, prevention, or therapeutic management of resistance, with conclusions supported by evidence appropriate to the study design.

Ownership

The journal is owned by OAE Publishing Inc.

Publishing Model

Gold open access. All articles published by CDR are made freely and permanently accessible online immediately from the date of publication. For further information, please refer to Open Access.

Copyright and License to Publish

Articles in CDR are published under a Creative Commons Attribution 4.0 International (CC BY 4.0). The CC BY 4.0 allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.

Copyright is retained by authors. Authors are required to sign a License to Publish (which can be downloaded from the journal's Author Instructions), granting CDR, which identifies itself as the original publisher, exclusive rights to publish their articles, and granting any third party the right to use the articles freely as long as the integrity is maintained and the original authors, citation details and publisher are identified.

Editorial Board

For more information about the editorial team, please refer to Editorial Board.

Editorial Policies

All manuscripts submitted to CDR should adhere to CDR's Editorial Policies.

Peer Review

The journal adheres to rigorous peer review and undergoes single-blind peer review. For more details, please refer to Editorial Process and Peer Review Guidelines.

Publication Ethics Statement

CDR is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best Practice Guidelines.

The Editors of this journal enforce a rigorous peer-review process together with strict ethical policies and standards to guarantee to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, image manipulation, inappropriate authorship credit, and the like, do arise. The Editors of CDR take such publishing ethics issues very seriously and are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use CrossCheck (powered by iThenticate) to check submissions against previous publications.

Journal Information and Statistics

• Launch date: 19 March 2018
• Publication model: Open access
• ISSN 2578-532X (Online)
• Digital archive: Portico
• Frequency: Continuously published
• DOI: 10.20517/cdr

Indexing & Archiving

• All articles published in CDR are included in:
• ESCI
• PMC
• Portico
• ROAD
• Worldcat
• Chaoxing "Domain" Publishing Platform
• BASE
• CAS
• Scopus
• Lens
• Dimensions
• CNKI
• J-Gate
• Embase
• ASCI

Contact

Please visit Contact Us for details about different queries.